|
1
|
Bonde JH, Sandri MT, Gary DS and Andrews
JC: Clinical utility of human papillomavirus genotyping in cervical
cancer screening: A systematic review. J Low Genit Tract Dis.
24:1–13. 2020. View Article : Google Scholar :
|
|
2
|
Wang R, Pan W, Jin L, Huang W, Li Y, Wu D,
Gao C, Ma D and Liao S: Human papillomavirus vaccine against
cervical cancer: Opportunity and challenge. Cancer Lett.
471:88–102. 2020. View Article : Google Scholar
|
|
3
|
Eskander RN and Tewari KS: Chemotherapy in
the treatment of metastatic, persistent, and recurrent cervical
cancer. Curr Opin Obstet Gynecol. 26:314–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Monk BJ and Tewari KS: Evidence-based
therapy for recurrent cervical cancer. J Clin Oncol. 32:2687–2690.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liontos M, Kyriazoglou A, Dimitriadis I,
Dimopoulos MA and Bamias A: Systemic therapy in cervical cancer: 30
years in review. Crit Rev Oncol Hematol. 137:9–17. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li H, Wu X and Cheng X: Advances in
diagnosis and treatment of metastatic cervical cancer. J Gynecol
Oncol. 27:e432016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gokduman K: Strategies targeting DNA
topoisomerase I in cancer chemotherapy: Camptothecins, nanocarriers
for camp-tothecins, organic non-camptothecin compounds and metal
complexes. Curr Drug Targets. 17:1928–1939. 2016. View Article : Google Scholar
|
|
8
|
Khanna C, Rosenberg M and Vail DM: A
review of paclitaxel and novel formulations including those
suitable for use in dogs. J Vet Intern Med. 29:1006–1012. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Newman DJ and Cragg GM: Natural products
as sources of new drugs over the 30 years from 1981 to 2010. J Nat
Prod. 75:311–335. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carter GT: Natural products and Pharma
2011: Strategic changes spur new opportunities. Nat Prod Rep.
28:1783–1789. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cragg GM and Newman DJ: Natural products:
A continuing source of novel drug leads. Biochim Biophys Acta.
1830:3670–3695. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Harvey AL, Edrada-Ebel R and Quinn RJ: The
re-emergence of natural products for drug discovery in the genomics
era. Nat Rev Drug Discov. 14:111–129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mishra BB and Tiwari VK: Natural products:
An evolving role in future drug discovery. Eur J Med Chem.
46:4769–4807. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Newman DJ and Cragg GM: Natural products
as sources of new drugs from 1981 to 2014. J Nat Prod. 79:629–661.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Patel S: Plant-derived cardiac glycosides:
Role in heart ailments and cancer management. Biomed Pharmacother.
84:1036–1041. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
López-Lázaro M, Pastor N, Azrak SS, Ayuso
MJ, Austin CA and Cortés F: Digitoxin inhibits the growth of cancer
cell lines at concentrations commonly found in cardiac patients. J
Nat Prod. 68:1642–1645. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang YZ, Chen X, Fan XX, He JX, Huang J,
Xiao DK, Zhou YL, Zheng SY, Xu JH, Yao XJ, et al: Compound library
screening identified cardiac glycoside digitoxin as an effective
growth inhibitor of gefitinib‑resistant non‑small cell lung cancer
via downregulation of α-tubulin and inhibition of microtubule
formation. Molecules. 21:3742016. View Article : Google Scholar
|
|
18
|
Iyer AKV, Zhou M, Azad N, Elbaz H, Wang L,
Rogalsky DK, Rojanasakul Y, O'Doherty GA and Langenhan JM: A direct
comparison of the anticancer activities of digitoxin
MeON-Neoglycosides and O-Glycosides: Oligosaccharide chain
length-dependent induction of caspase-9-mediated apoptosis. ACS Med
Chem Lett. 1:326–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Trenti A, Boscaro C, Tedesco S, Cignarella
A, Trevisi L and Bolego C: Effects of digitoxin on cell migration
in ovarian cancer inflammatory microenvironment. Biochem Pharmacol.
154:414–423. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hsu IL, Chou CY, Wu YY, Wu JE, Liang CH,
Tsai YT, Ke JY, Chen YL, Hsu KF and Hong TM: Targeting FXYD2 by
cardiac glycosides potently blocks tumor growth in ovarian clear
cell carcinoma. Oncotarget. 7:62925–62938. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Prassas I, Karagiannis GS, Batruch I,
Dimitromanolakis A, Datti A and Diamandis EP: Digitoxin-induced
cytotoxicity in cancer cells is mediated through distinct kinase
and interferon signaling networks. Mol Cancer Ther. 10:2083–2093.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shang Z and Zhang L: Digitoxin increases
sensitivity of glioma stem cells to TRAIL-mediated apoptosis.
Neurosci Lett. 653:19–24. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee DH, Cheul Oh S, Giles AJ, Jung J,
Gilbert MR and Park DM: Cardiac glycosides suppress the maintenance
of stemness and malignancy via inhibiting HIF-1α in human glioma
stem cells. Oncotarget. 8:40233–40245. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pollard BS, Suckow MA, Wolter WR, Starr
JM, Eidelman O, Dalgard CL, Kumar P, Battacharyya S, Srivastava M,
Biswas R, et al: Digitoxin Inhibits
epithelial-to-mesenchymal-transition in hereditary castration
resistant prostate cancer. Front Oncol. 9:6302019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu M, Feng LX, Sun P, Liu W, Mi T, Lei M,
Wu W, Jiang B, Yang M, Hu L, et al: Knockdown of apolipoprotein E
enhanced sensitivity of Hep3B cells to cardiac steroids via
regulating Na+/K+-ATPase signalosome. Mol Cancer Ther.
15:2955–2965. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Felth J, Rickardson L, Rosén J, Wickström
M, Fryknäs M, Lindskog M, Bohlin L and Gullbo J: Cytotoxic effects
of cardiac glycosides in colon cancer cells, alone and in
combination with standard chemotherapeutic drugs. J Nat Prod.
72:1969–1974. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiao Y, Yan W, Guo L, Meng C, Li B, Neves
H, Chen PC, Li L, Huang Y, Kwok HF, et al: Digitoxin synergizes
with sorafenib to inhibit hepatocelluar carcinoma cell growth
without inhibiting cell migration. Mol Med Rep. 15:941–947. 2017.
View Article : Google Scholar
|
|
28
|
Einbond LS, Shimizu M, Ma H, Wu HA,
Goldsberry S, Sicular S, Panjikaran M, Genovese G and Cruz E:
Actein inhibits the Na+-K+-ATPase and enhances the growth
inhibitory effect of digitoxin on human breast cancer cells.
Biochem Biophys Res Commun. 375:608–613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Einbond LS, Wu HA, Sandu C, Ford M, Mighty
J, Antonetti V, Redenti S and Ma H: Digitoxin enhances the growth
inhibitory effects of thapsigargin and simvastatin on ER negative
human breast cancer cells. Fitoterapia. 109:146–154. 2016.
View Article : Google Scholar
|
|
30
|
Kulkarni YM, Kaushik V, Azad N, Wright C,
Rojanasakul Y, O'Doherty G and Iyer AK: Autophagy-induced apoptosis
in lung cancer cells by a novel digitoxin analog. J Cell Physiol.
231:817–828. 2016. View Article : Google Scholar :
|
|
31
|
Trenti A, Zulato E, Pasqualini L,
Indraccolo S, Bolego C and Trevisi L: Therapeutic concentrations of
digitoxin inhibit endothelial focal adhesion kinase and
angiogenesis induced by different growth factors. Br J Pharmacol.
174:3094–3106. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deng LJ, Peng QL, Wang LH, Xu J, Liu JS,
Li YJ, Zhuo ZJ, Bai LL, Hu LP, Chen WM, et al: Arenobufagin
intercalates with DNA leading to G2 cell cycle arrest via ATM/ATR
pathway. Oncotarget. 6:34258–34275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Silva IT, Munkert J, Nolte E, Zanchett
Schneider NF, Carvalho Rocha S, Pacheco Ramos AC, Kreis W, Castro
Braga F, de Pádua RM, et al: Cytotoxicity of AMANTADIG - a
semi-synthetic digitoxigenin derivative - alone and in combination
with docetaxel in human hormone-refractory prostate cancer cells
and its effect on Na+/K+-ATPase inhibition.
Biomed Pharmacother. 107:464–474. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Johansson S, Lindholm P, Gullbo J, Larsson
R, Bohlin L and Claeson P: Cytotoxicity of digitoxin and related
cardiac glycosides in human tumor cells. Anticancer Drugs.
12:475–483. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Marzo-Mas A, Barbier P, Breuzard G,
Allegro D, Falomir E, Murga J, Carda M, Peyrot V and Marco JA:
Interactions of long-chain homologues of colchicine with tubulin.
Eur J Med Chem. 126:526–535. 2017. View Article : Google Scholar
|
|
36
|
Stark GR and Taylor WR: Control of the
G2/M transition. Mol Biotechnol. 32:227–248. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kastan MB and Bartek J: Cell-cycle
checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Löbrich M, Shibata A, Beucher A, Fisher A,
Ensminger M, Goodarzi AA, Barton O and Jeggo PA: gammaH2AX foci
analysis for monitoring DNA double-strand break repair: Strengths,
limitations and optimization. Cell Cycle. 9:662–669. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Matsuoka S, Rotman G, Ogawa A, Shiloh Y,
Tamai K and Elledge SJ: Ataxia telangiectasia-mutated
phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA.
97:10389–10394. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao H and Piwnica-Worms H: ATR-mediated
checkpoint pathways regulate phosphorylation and activation of
human Chk1. Mol Cell Biol. 21:4129–4139. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Perdiguero E and Nebreda AR: Regulation of
Cdc25C activity during the meiotic G2/M transition. Cell Cycle.
3:733–737. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gupta S and Bhattacharyya B:
Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell
Biochem. 253:41–47. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jordan MA, Thrower D and Wilson L, Jordan
MA, Thrower D and Wilson L: Mechanism of inhibition of cell
proliferation by Vinca alkaloids. Cancer Res. 51:2212–2222.
1991.PubMed/NCBI
|
|
44
|
Johnson IS, Armstrong JG, Gorman M and
Burnett JP Jr: The vinca alkaloids, a new class of oncolytic
agents. Cancer Res. 23:1390–1427. 1963.PubMed/NCBI
|
|
45
|
Sadeghi-Aliabadi H, Minaiyan M and
Dabestan A: Cytotoxic evaluation of doxorubicin in combination with
simvastatin against human cancer cells. Res Pharm Sci. 5:127–133.
2010.PubMed/NCBI
|
|
46
|
Yin Y, Lian BP, Xia YZ, Shao YY and Kong
LY: Design, synthesis and biological evaluation of
resveratrol-cinnamoyl derivates as tubulin polymerization
inhibitors targeting the colchicine binding site. Bioorg Chem.
93:1033192019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hosseini M, Taherkhani M and Ghorbani
Nohooji M: Introduction of Adonis aestivalis as a new source of
effective cytotoxic cardiac glycoside. Nat Prod Res. 33:915–920.
2019. View Article : Google Scholar
|
|
48
|
Laiho M and Latonen L: Cell cycle control,
DNA damage checkpoints and cancer. Ann Med. 35:391–397. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Harper JW and Elledge SJ: The DNA damage
response: Ten years after. Mol Cell. 28:739–745. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Durocher D and Jackson SP: DNA-PK, ATM and
ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell
Biol. 13:225–231. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Elbaz HA, Stueckle TA, Wang HYL, O'Doherty
GA, Lowry DT, Sargent LM, Wang L, Dinu CZ and Rojanasakul Y:
Digitoxin and a synthetic monosaccharide analog inhibit cell
viability in lung cancer cells. Toxicol Appl Pharmacol. 258:51–60.
2012. View Article : Google Scholar :
|
|
52
|
Nurse P: A long twentieth century of the
cell cycle and beyond. Cell. 100:71–78. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bloom J and Cross FR: Multiple levels of
cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol.
8:149–160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fisher DL and Nurse P: A single fission
yeast mitotic cyclin B p34cdc2 kinase promotes both S-phase and
mitosis in the absence of G1 cyclins. EMBO J. 15:850–860. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hayles J, Fisher D, Woollard A and Nurse
P: Temporal order of S phase and mitosis in fission yeast is
determined by the state of the p34cdc2-mitotic B cyclin complex.
Cell. 78:813–822. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gould KL and Nurse P: Tyrosine
phosphorylation of the fission yeast cdc2+ protein kinase regulates
entry into mitosis. Nature. 342:39–45. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Rahimtoola SH: Digitalis therapy for
patients in clinical heart failure. Circulation. 109:2942–2946.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lapostolle F, Borron SW, Verdier C,
Taboulet P, Guerrier G, Adnet F, Clemessy JL, Bismuth C and Baud
FJ: Digoxin‑specific Fab fragments as single first‑line therapy in
digitalis poisoning. Crit Care Med. 36:3014–3018. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Haux J, Klepp O, Spigset O and Tretli S:
Digitoxin medication and cancer; case control and internal
dose-response studies. BMC Cancer. 1:112001. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Eskiocak U, Ramesh V, Gill JG, Zhao Z,
Yuan SW, Wang M, Vandergriff T, Shackleton M, Quintana E, Johnson
TM, et al: Synergistic effects of ion transporter and MAP kinase
pathway inhibitors in melanoma. Nat Commun. 7:123362016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Daniel D, Süsal C, Kopp B, Opelz G and
Terness P: Apoptosis-mediated selective killing of malignant cells
by cardiac steroids: maintenance of cytotoxicity and loss of
cardiac activity of chemically modified derivatives. Int
Immunopharmacol. 3:1791–1801. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
López-Lázaro M: Digitoxin as an anticancer
agent with selectivity for cancer cells: Possible mechanisms
involved. Expert Opin Ther Targets. 11:1043–1053. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhao B, Kim J, Ye X, Lai ZC and Guan KL:
Both TEAD-binding and WW domains are required for the growth
stimulation and oncogenic transformation activity of yes-associated
protein. Cancer Res. 69:1089–1098. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yakisich JS, Azad N, Venkatadri R,
Kulkarni Y, Wright C, Kaushik V, O'Doherty GA and Iyer AK:
Digitoxin and its synthetic analog MonoD have potent
antiproliferative effects on lung cancer cells and potentiate the
effects of hydroxyurea and paclitaxel. Oncol Rep. 35:878–886. 2016.
View Article : Google Scholar :
|
